Kate advises clients on all issues relating to the enforcement and validity of patents and supplementary protection certificates, as well as IP licensing disputes. Her previous cases have involved antibody technology, small molecules, medical devices and dosage regimens. Kate has experience of litigating in the UK High Court and Court of Appeal, as well as coordinating cross-border disputes in Europe, Asia and North America.

Some of Kate’s work highlights include:

• Accord v Novartis – successfully defended Novartis before the Patents Court in the Entresto^® (sacubitril/valsartan) litigation, and multi-jurisdictional coordination.
• Teva and Samsung Bioepis v Novartis – UK patent litigation relating to ranibizumab pre-filled syringes, and multi-jurisdictional coordination.
• Lilly v Novartis; UCB v Novartis – patent revocation and infringement proceedings relating to IL-17A/F antibody patents, and multi-jurisdictional coordination.
• Otsuka v GW Pharma – IP licence dispute relating to cannabidiol treatment for epilepsy.
• Coordinating multinational patent litigation strategies for blockbuster pharmaceutical biologic products in Europe, Asia and North America.
• Advising on patents to checkpoint inhibitors antibodies for use in various cancers, and supporting associated EPO opposition and appeal proceedings.